The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | Securing SABR: improving access in the UK
With recent data showing that stereotactic ablative body radiotherapy (SABR) improves outcomes in early stage and oligometastatic lung cancer, improving access to this treatment is a priority, as discussed here by Iain Phillips, MBBS, BSc, MSc, MRCP, FRCR, of NHS Lothian, Edinburgh, UK. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.
